Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia

Southern Medical Journal

Volumn 90, Issue 5, 1997, Pages 509-523

  McKiernan, James M ^a,b   Lowe, Franklin C ^a,b  

^a Columbia Presbyterian Medical Center ^*

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TERAZOSIN;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EDEMA; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; ORAL DRUG ADMINISTRATION; PROSTATE HYPERTROPHY; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO;

EID: 0030929074     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199705000-00009     Document Type: Article

References (20)

1. Lowe FC, Stark E: The use of alpha-blockers in the management of benign prostatic hyperplasia. NY State J Med 1993; 93:169-173
2. Lowe FC, Lepor H: Alpha-blockade in the management of benign prostatic hyperplasia. Alternate Methods for the Managment of BPH. Romas NA, Vaughan ED (eds). Berlin, Springer-Verlag, 1993, pp 173-183
3. Boreham PF, Braithwaite P, Milewski P, et al: Alpha adrenergic blockers in prostatism. Br J Surg 1977; 64:756-757
4. Caine M, Pfau A, Perlberg S: The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 1976; 48:255-263
5. Caine M, Perlberg S, Meretyk S: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50:551-554
6. Abrams PH, Shah PJ, Stone R, et al: Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982; 54:527-530
7. Lepor H: Nonoperative management of benign prostatic hyperplasia. J Urol 1989; 141:1283-1289
8. Eri LM, Tveter JK: Alpha blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995; 154:923-934
9. Lepor H, Auerbach S, Puras-Baez A, et al: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148:1467-1474
10. McConnell JD, Barry MJ, Bruskewitz RC, et al: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline Number 8, US Department of Health and Human Services, Agency for Health Care Policy and Research. No. 94-0582, Feb 1994
11. Lowe FC: Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperlasia: a combined analysis. Urology 1994; 44:46-51
12. Lloyd SN, Buckley JF, Chilton CP, et al: Terazosin in the treatment of benign prostatic hyperplasia: a multicenter, placebo-controlled trial. Br J Urol 1992; 70(suppl 1):17-21
13. Di Silverio F: Terazosin in the treatment of benign prostatic hyperplasia: experience in Italy. Br J Urol 1992; 70(suppl 1):22-26
14. Brawer MK, Adams G, Epstein H: Treatment of benign prostatic hyperplasia. Arch Fam Med 1993; 2:929-935
15. Roehrborn CG, Oesterling JE, Auerbach S, et al: The Hytrin Community Assessment Trial study: a one year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996; 47:159-168
16. Lepor H: Clinical evaluation of tamsulosin, a prostate selective alpha 1c antagonist. J Urol 1995; 153(suppl):274A
17. Kaplan SA, Meade-D'Alisera P, Qinones S, et al: Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology 1995; 46:512-517
18. Lowe FC, Tuttle J, Marks S, et al, for the HYCAT Investigator Group: Blood pressure effects of men with prostatism concurrently treated with antihypertensives and terazosin. J Urol 1995; 153:272A
19. Cohen J: Long term efficacy and safety of terazosin. J Clin Pharmacol 1993; 33:272-278
20. Holme I: An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82:1916-1924